This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roblin, P. M.
Right arrow Articles by Hammerschlag, M. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1515-1516, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae

Patricia M. Roblin and Margaret R. Hammerschlag*

Division of Infectious Diseases, Department of Pediatrics, SUNY Health Science Center at Brooklyn, Brooklyn, New York 11203

Received 13 January 1998/Returned for modification 4 March 1998/Accepted 26 March 1998

The in vitro activities of HMR 3647, roxithromycin, erythromycin, and azithromycin against 19 strains of Chlamydia pneumoniae were tested. The MIC at which 90% of the isolates are inhibited and the minimum bactericidal concentration at which 90% of the isolates are killed of HMR 3647 were 0.25 µg/ml (range, 0.015 to 2 µg/ml). Nine recently obtained clinical isolates from children with pneumonia were more susceptible (MICs, 0.015 to 0.0625 µg/ml) than older strains that had been passaged more extensively.

* Corresponding author. Mailing address: Department of Pediatrics, Box 49, SUNY Health Science Center at Brooklyn, 450 Clarkson Ave., Brooklyn, NY 11203-2098. Phone: (718) 245-4075. Fax: (718) 245-2118. E-mail: mhammerschlag{at}pol.net.

Antimicrobial Agents and Chemotherapy, June 1998, p. 1515-1516, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lee, J. H., Cho, Y. K., Jung, Y. S., Kim, Y. C., Lee, M. G. (2008). Effects of Escherichia coli Lipopolysaccharide on Telithromycin Pharmacokinetics in Rats: Inhibition of Metabolism via CYP3A. Antimicrob. Agents Chemother. 52: 1046-1051 [Abstract] [Full Text]  
  • Kim, D.-M., Yu, K. D., Lee, J. H., Kim, H. K., Lee, S.-H. (2007). Controlled Trial of a 5-Day Course of Telithromycin versus Doxycycline for Treatment of Mild to Moderate Scrub Typhus. Antimicrob. Agents Chemother. 51: 2011-2015 [Abstract] [Full Text]  
  • Dorbecker, C., Sander, A., Oberle, K., Schulin-Casonato, T. (2006). In vitro susceptibility of Bartonella species to 17 antimicrobial compounds: comparison of Etest and agar dilution. J Antimicrob Chemother 58: 784-788 [Abstract] [Full Text]  
  • Johnston, S. L., Blasi, F., Black, P. N., Martin, R. J., Farrell, D. J., Nieman, R. B., the TELICAST Investigators, (2006). The Effect of Telithromycin in Acute Exacerbations of Asthma. NEJM 354: 1589-1600 [Abstract] [Full Text]  
  • Brook, I., Hausfeld, J. N. (2006). Effect of telithromycin and azithromycin on nasopharyngeal bacterial flora in patients with acute maxillary sinusitis.. Arch Otolaryngol Head Neck Surg 132: 442-445 [Abstract] [Full Text]  
  • Fogarty, C., de Wet, R., Mandell, L., Chang, J., Rangaraju, M., Nusrat, R. (2005). Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization. Chest 128: 1980-1988 [Abstract] [Full Text]  
  • Kasbekar, N., Acharya, P. S. (2005). Telithromycin: The first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm 62: 905-916 [Abstract] [Full Text]  
  • Tormakangas, L., Alakarppa, H., David, D. B., Leinonen, M., Saikku, P. (2004). Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice. Antimicrob. Agents Chemother. 48: 3655-3661 [Abstract] [Full Text]  
  • Hammerschlag, M. R., Roblin, P. M. (2004). The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J Antimicrob Chemother 54: 281-282 [Full Text]  
  • Tormakangas, L., Saario, E., Bem David, D., Bryskier, A., Leinonen, M., Saikku, P. (2004). Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice. J Antimicrob Chemother 53: 1101-1104 [Abstract] [Full Text]  
  • Muller-Serieys, C., Andrews, J., Vacheron, F., Cantalloube, C. (2004). Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 53: 149-157 [Abstract] [Full Text]  
  • Miyashita, N., Fukano, H., Yoshida, K., Niki, Y., Matsushima, T. (2003). In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 52: 497-499 [Abstract] [Full Text]  
  • Clark, J. P., Langston, E. (2003). Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting. Mayo Clin Proc. 78: 1113-1124 [Abstract]  
  • Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
  • Maurin, M., Bryskier, A., Raoult, D. (2002). Antibiotic Susceptibilities of Parachlamydia acanthamoeba in Amoebae. Antimicrob. Agents Chemother. 46: 3065-3067 [Abstract] [Full Text]  
  • Vazifeh, D., Abdelghaffar, H., Labro, M. T. (2002). Effect of Telithromycin (HMR 3647) on Polymorphonuclear Neutrophil Killing of Staphylococcus aureus in Comparison with Roxithromycin. Antimicrob. Agents Chemother. 46: 1364-1374 [Abstract] [Full Text]  
  • Kadota, J.-I., Ishimatsu, Y., Iwashita, T., Matsubara, Y., Tomono, K., Tateno, M., Ishihara, R., Muller-Serieys, C., Kohno, S. (2002). Intrapulmonary Pharmacokinetics of Telithromycin, a New Ketolide, in Healthy Japanese Volunteers. Antimicrob. Agents Chemother. 46: 917-921 [Abstract] [Full Text]  
  • Boman, J., Hammerschlag, M. R. (2002). Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. Clin. Microbiol. Rev. 15: 1-20 [Abstract] [Full Text]  
  • Muller-Serieys, C., Soler, P., Cantalloube, C., Lemaitre, F., Gia, H. P., Brunner, F., Andremont, A. (2001). Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647). Antimicrob. Agents Chemother. 45: 3104-3108 [Abstract] [Full Text]  
  • Miyashita, N., Fukano, H., Niki, Y., Matsushima, T. (2001). In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 48: 403-405 [Abstract] [Full Text]  
  • Vester, B., Douthwaite, S. (2001). Macrolide Resistance Conferred by Base Substitutions in 23S rRNA. Antimicrob. Agents Chemother. 45: 1-12 [Full Text]  
  • Maurin, M., Mersali, N. F., Raoult, D. (2000). Bactericidal Activities of Antibiotics against Intracellular Francisella tularensis. Antimicrob. Agents Chemother. 44: 3428-3431 [Abstract] [Full Text]  
  • Rastogi, N., Goh, K. S., Berchel, M., Bryskier, A. (2000). In Vitro Activities of the Ketolides Telithromycin (HMR 3647) and HMR 3004 Compared to Those of Clarithromycin against Slowly Growing Mycobacteria at pHs 6.8 and 7.4. Antimicrob. Agents Chemother. 44: 2848-2852 [Abstract] [Full Text]  
  • Gustafsson, I., Hjelm, E., Cars, O. (2000). In Vitro Pharmacodynamics of the New Ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 44: 1846-1849 [Abstract] [Full Text]  
  • Rolain, J.-M., Maurin, M., Bryskier, A., Raoult, D. (2000). In Vitro Activities of Telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis. Antimicrob. Agents Chemother. 44: 1391-1393 [Abstract] [Full Text]  
  • Strigl, S., Roblin, P. M., Reznik, T., Hammerschlag, M. R. (2000). In Vitro Activity of ABT 773, a New Ketolide Antibiotic, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 44: 1112-1113 [Abstract] [Full Text]  
  • Freidank, H. M., Losch, P., Vögele, H., Wiedmann-Al-Ahmad, M. (1999). In Vitro Susceptibilities of Chlamydia pneumoniae Isolates from German Patients and Synergistic Activity of Antibiotic Combinations. Antimicrob. Agents Chemother. 43: 1808-1810 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»